Novartis Ag

Novartis Pharma Gmbh

Markus Ahlheim

Dierk Wieckhusen

Alexandra Glausch

Olivier Lambert

Michael Ausborn

Marc Riemenschnitter

Rolf Loeffler

Holger Petersen

Rolf Löffler

The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).

Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers

A depot formulation comprising iloperidone and a biodegradable, biocompatible polymer. Preferably, the polymer is a star polymer.

Organic compounds

An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.

Injectable depot formulation comprising crystals of iloperidone

Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.

Growing community of inventors

Staufen, Germany

Markus Ahlheim